Class Action Lawsuit Filed Against ADMA Biologics: Investors Encouraged to Act Now

A Warning to ADMA Biologics Investors

In a noteworthy development for shareholders of ADMA Biologics, Inc., Pomerantz Law Firm has announced the initiation of a class action lawsuit against the company, listed on NASDAQ under the ticker symbol ADMA. This legal action arises from allegations pertaining to potential securities fraud and improper business practices that could significantly affect the financial interests of investors who acquired shares during a specified time frame known as the 'Class Period.'

Details of the Lawsuit

According to Pomerantz LLP, the class action aims to address serious claims suggesting that ADMA Biologics, along with specific officers and directors, may have engaged in deceptive practices regarding the company’s financial performance and disclosures. Individuals who purchased or secured shares in ADMA are advised to reach out to the firm for assistance in joining the lawsuit, with the deadline to apply as Lead Plaintiff set for August 10, 2026. Interested parties should contact Danielle Peyton at the provided email or call the designated toll-free number.

Allegations from Analysts

The allegations came into sharper focus following a damaging report by Culper Research published on March 24, 2026. The report accused ADMA of artificial inflation of revenues through questionable sales tactics, ultimately claiming that the company’s purported growth figures were overstated due to a 'channel stuffing scheme.' This refers to the practice of causing a higher number of goods to be sold to distributors than end customers can consume, thereby artificially inflating revenue figures.

Immediately following the release of these allegations, ADMA's stock price suffered a significant drop, falling by $2.26 or roughly 16.63%, closing at $11.33 per share. The negative sentiments surrounding the report were compounded two days later when Cantor Fitzgerald downgraded ADMA’s stock rating, citing insufficient responses to the accusations brought forth by Culper Research. Following this downgrade, the stock price declined further, closing at $8.29 per share, a notable drop of $1.34 or 13.91%.

The Quest for Justice

Pomerantz LLP, a firm with a distinguished reputation in securities litigation, emphasizes that shareholders have the right to pursue legal redress if they believe they’ve been misled or suffered losses due to corporate malpractice. Founded by Abraham L. Pomerantz, often referred to as the dean of the class action bar, the firm has been at the forefront of protecting investors for over 85 years. They continue this legacy by advocating for those affected by securities fraud and misconduct, achieving significant settlements and judgments on behalf of class-action plaintiffs.

The firm underscores the importance of taking swift action in such cases to safeguard one's rights and potential recoveries. Interested investors are encouraged to stay informed about the litigation process and consider the possibility of joining the legal claim to enhance their chances of financial recovery.

For further engagement, potential claimants can view the full complaint and related documents by visiting the Pomerantz Law Firm’s official website.

Taking Action

In light of these events, ADMA Biologics investors are urged to monitor the developments closely. Given the current legal climate surrounding the company, timely participation in the class action may be crucial for those seeking to make claims regarding their investments. With the deadline approaching, now is the time to act to protect your interests.

For more information on representation or to join the class action lawsuit, please contact Pomerantz Law Firm directly.

This situation serves as a critical reminder for investors to remain vigilant and proactive in safeguarding their investments, especially in the face of allegations that can result in significant financial repercussions. As the lawsuit progresses, further updates are anticipated that could impact the outlook for ADMA Biologics investors.